Zurich Cantonal Bank’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Zurich Cantonal Bank’s Portfolio EIGR Stock Details EIGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-144	Closed	-$22K	–	2869
2021 Q4	$22K	Sell	144 -15	-9%	-$2.9K	﹤0.01%	2852
2021 Q3	$32K	Buy	159 +1	+0.6%	+$238	﹤0.01%	2729
2021 Q2	$40K	Buy	158 +12	+8%	+$3K	﹤0.01%	2502
2021 Q1	$39K	Buy	+146	New	+$46K	﹤0.01%	2460

Other funds holding EIGR

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Zurich Cantonal Bank's EIGR Position: Q1 2022 in Review

Zurich Cantonal Bank sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q1 2022, closing a stake of 144 shares — an estimated $22K sold.

Zurich Cantonal Bank first reported a position in EIGR in Q1 2021 and held it in 4 quarters. The position peaked at $40K in Q2 2021. 94 funds tracked by Wall St. Rank hold EIGR as of Q1 2022.

Zurich Cantonal Bank reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q1 2022 after selling out during the quarter.
Zurich Cantonal Bank sold 144 Eiger BioPharmaceuticals, Inc. shares in Q1 2022, an estimated $22K.
Zurich Cantonal Bank first reported a position in Eiger BioPharmaceuticals, Inc. in Q1 2021 and held it in 4 quarters.
Zurich Cantonal Bank's Eiger BioPharmaceuticals, Inc. position peaked at $40K in Q2 2021.
94 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q1 2022.

Based on Zurich Cantonal Bank's 13F filing for Q1 2022, filed 21 Apr 2022.